Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Idres, N; Benoit, G; Flexor, MA; Lanotte, M; Chabot, GG
   Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites
   CANCER RESEARCH
   
   N. Idres et al., "Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites", CANCER RES, 61(2), 2001, pp. 700-705
2. Marill, J; Cresteil, T; Lanotte, M; Chabot, GG
   Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites
   MOLECULAR PHARMACOLOGY
   
   J. Marill et al., "Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites", MOLEC PHARM, 58(6), 2000, pp. 1341-1348
3. Chabot, GG; Robert, J; Lokiec, F; Canal, P
   Irinotecan pharmacokinetics
   BULLETIN DU CANCER
   
   G.G. Chabot et al., "Irinotecan pharmacokinetics", B CANCER, 1998, pp. 11-20
4. CHABOT GG
   CLINICAL PHARMACOKINETICS OF IRINOTECAN
   Clinical pharmacokinetics
   
   G.G. Chabot, "CLINICAL PHARMACOKINETICS OF IRINOTECAN", Clinical pharmacokinetics, 33(4), 1997, pp. 245-259
5. DAUZONNE D; FOLLEAS B; MARTINEZ L; CHABOT GG
   SYNTHESIS AND IN-VITRO CYTOTOXICITY OF A SERIES OF 3-AMINOFLAVONES
   European journal of medicinal chemistry
   
   D. Dauzonne et al., "SYNTHESIS AND IN-VITRO CYTOTOXICITY OF A SERIES OF 3-AMINOFLAVONES", European journal of medicinal chemistry, 32(1), 1997, pp. 71-82
6. MAHNKE Z; STROTKAMP D; ROOS PH; HANSTEIN WG; CHABOT GG; NEF P
   EXPRESSION AND INDUCIBILITY OF CYTOCHROME-P450-3A9 (CYP3A9) AND OTHERMEMBERS OF THE CYP3A-SUBFAMILY IN RAT-LIVER
   Archives of biochemistry and biophysics
   
   Z. Mahnke et al., "EXPRESSION AND INDUCIBILITY OF CYTOCHROME-P450-3A9 (CYP3A9) AND OTHERMEMBERS OF THE CYP3A-SUBFAMILY IN RAT-LIVER", Archives of biochemistry and biophysics, 337(1), 1997, pp. 62-68
7. BISSERY MC; VRIGNAUD P; LAVELLE F; CHABOT GG
   EXPERIMENTAL ANTITUMOR-ACTIVITY AND PHARMACOKINETICS OF THE CAMPTOTHECIN ANALOG IRINOTECAN (CPT-11) IN MICE
   Anti-cancer drugs
   
   M.C. Bissery et al., "EXPERIMENTAL ANTITUMOR-ACTIVITY AND PHARMACOKINETICS OF THE CAMPTOTHECIN ANALOG IRINOTECAN (CPT-11) IN MICE", Anti-cancer drugs, 7(4), 1996, pp. 437-460
8. ABIGERGES D; ARMAND JP; CHABOT GG; BRUNO R; BISSERY MC; BAYSSAS M; KLINKALAKL M; CLAVEL M; CATIMEL G
   PHASE-I AND PHARMACOLOGY STUDY OF INTOPLICINE (RP-60475 NSC-645008), A NOVEL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, IN CANCER-PATIENTS
   Anti-cancer drugs
   
   D. Abigerges et al., "PHASE-I AND PHARMACOLOGY STUDY OF INTOPLICINE (RP-60475 NSC-645008), A NOVEL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR, IN CANCER-PATIENTS", Anti-cancer drugs, 7(2), 1996, pp. 166-174
9. CHABOT GG; ARMAND JP; TERRET C; DEFORNI M; ABIGERGES D; WINOGRAD B; IGWEMEZIE L; SCHACTER L; KAUL S; ROPERS J; BONNAY M
   ETOPOSIDE BIOAVAILABILITY AFTER ORAL-ADMINISTRATION OF THE PRODRUG ETOPOSIDE PHOSPHATE IN CANCER-PATIENTS DURING A PHASE-I STUDY
   Journal of clinical oncology
   
   G.G. Chabot et al., "ETOPOSIDE BIOAVAILABILITY AFTER ORAL-ADMINISTRATION OF THE PRODRUG ETOPOSIDE PHOSPHATE IN CANCER-PATIENTS DURING A PHASE-I STUDY", Journal of clinical oncology, 14(7), 1996, pp. 2020-2030
10. MAHNKE A; ROOS PH; HANSTEIN WG; CHABOT GG
    IN-VIVO INDUCTION OF CYTOCHROME-P450 CYP3A EXPRESSION IN RAT LEUKOCYTES USING VARIOUS INDUCERS
    Biochemical pharmacology
    
    A. Mahnke et al., "IN-VIVO INDUCTION OF CYTOCHROME-P450 CYP3A EXPRESSION IN RAT LEUKOCYTES USING VARIOUS INDUCERS", Biochemical pharmacology, 51(11), 1996, pp. 1579-1582
11. RIBRAG V; MASSAAD L; JANOT F; MORIZET J; GOUYETTE A; CHABOT GG
    MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN HUMAN NON-HODGKINS-LYMPHOMASSENSITIVE OR RESISTANT TO CHEMOTHERAPY
    Leukemia & lymphoma
    
    V. Ribrag et al., "MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN HUMAN NON-HODGKINS-LYMPHOMASSENSITIVE OR RESISTANT TO CHEMOTHERAPY", Leukemia & lymphoma, 18(3-4), 1995, pp. 303-310
12. CATIMEL G; CHABOT GG; GUASTALLA JP; DUMORTIER A; COTE C; ENGEL C; GOUYETTE A; MATHIEUBOUE A; MAHJOUBI M; CLAVEL M
    PHASE-I AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) ADMINISTEREDDAILY FOR 3 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED SOLID TUMORS
    Annals of oncology
    
    G. Catimel et al., "PHASE-I AND PHARMACOKINETIC STUDY OF IRINOTECAN (CPT-11) ADMINISTEREDDAILY FOR 3 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED SOLID TUMORS", Annals of oncology, 6(2), 1995, pp. 133-140
13. CHABOT GG; ABIGERGES D; CATIMEL G; CULINE S; DEFORNI R; EXTRA JM; MAHJOUBI H; HERAIT P; ARMAND JP; BUGAT R; CLAVEL M; MARTY ME
    POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS
    Annals of oncology
    
    G.G. Chabot et al., "POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF IRINOTECAN (CPT-11) AND ACTIVE METABOLITE SN-38 DURING PHASE-I TRIALS", Annals of oncology, 6(2), 1995, pp. 141-151
14. ABIGERGES D; CHABOT GG; ARMAND JP; HERAIT P; GOUYETTE A; GANDIA D
    PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS
    Journal of clinical oncology
    
    D. Abigerges et al., "PHASE-I AND PHARMACOLOGICAL STUDIES OF THE CAMPTOTHECIN ANALOG IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN CANCER-PATIENTS", Journal of clinical oncology, 13(1), 1995, pp. 210-221
15. CHABOT GG
    LIMITED SAMPLING MODELS FOR SIMULTANEOUS ESTIMATION OF THE PHARMACOKINETICS OF IRINOTECAN AND ITS ACTIVE METABOLITE SN-38
    Cancer chemotherapy and pharmacology
    
    G.G. Chabot, "LIMITED SAMPLING MODELS FOR SIMULTANEOUS ESTIMATION OF THE PHARMACOKINETICS OF IRINOTECAN AND ITS ACTIVE METABOLITE SN-38", Cancer chemotherapy and pharmacology, 36(6), 1995, pp. 463-472
16. DEFORNI M; CHABOT GG; ARMAND JP; GOUYETTE A; KLINKALAK M; RECONDO G
    PHASE-I AND PHARMACOLOGY STUDY OF FLAVONE ACETIC-ACID ADMINISTERED 2 OR 3 TIMES WEEKLY WITHOUT ALKALINIZATION
    Cancer chemotherapy and pharmacology
    
    M. Deforni et al., "PHASE-I AND PHARMACOLOGY STUDY OF FLAVONE ACETIC-ACID ADMINISTERED 2 OR 3 TIMES WEEKLY WITHOUT ALKALINIZATION", Cancer chemotherapy and pharmacology, 35(3), 1995, pp. 219-224
17. PARISE O; JANOT F; LUBOINSKI B; MASSAAD L; ALBIN N; TOUSSAINT C; VERJUS MA; BONNAY M; GOUYETTE A; CHABOT GG
    THYMIDYLATE SYNTHASE ACTIVITY, FOLATES, AND GLUTATHIONE SYSTEM IN HEAD AND NECK-CARCINOMA AND ADJACENT TISSUES
    Head & neck
    
    O. Parise et al., "THYMIDYLATE SYNTHASE ACTIVITY, FOLATES, AND GLUTATHIONE SYSTEM IN HEAD AND NECK-CARCINOMA AND ADJACENT TISSUES", Head & neck, 16(2), 1994, pp. 158-164
18. MUNCK JN; ROUGIER P; CHABOT GG; RAMIREZ LH; BOGNEL C; LUMBROSO J; HERAIT P; ELIAS D; LASSER P; GOUYETTE A
    PHASE-I AND PHARMACOLOGICAL STUDY OF INTRAARTERIAL HEPATIC ADMINISTRATION OF PIRARUBICIN IN PATIENTS WITH ADVANCED HEPATIC METASTASES
    European journal of cancer
    
    J.N. Munck et al., "PHASE-I AND PHARMACOLOGICAL STUDY OF INTRAARTERIAL HEPATIC ADMINISTRATION OF PIRARUBICIN IN PATIENTS WITH ADVANCED HEPATIC METASTASES", European journal of cancer, 30A(3), 1994, pp. 289-294
19. TOUSSAINT C; IZZO J; SPIELMANN M; MERLE S; MAYLEVIN F; ARMAND JP; LACOMBE D; TURSZ T; SUNDERLAND M; CHABOT GG; CVITKOVIC E
    PHASE I II TRIAL OF CONTINUOUS-INFUSION VINORELBINE FOR ADVANCED BREAST-CANCER/
    Journal of clinical oncology
    
    C. Toussaint et al., "PHASE I II TRIAL OF CONTINUOUS-INFUSION VINORELBINE FOR ADVANCED BREAST-CANCER/", Journal of clinical oncology, 12(10), 1994, pp. 2102-2112
20. MASSAAD L; CHABOT GG; TOUSSAINT C; KOSCIELNY S; MORIZET J; BISSERY MC; GOUYETTE A
    INFLUENCE OF TUMOR SIZE ON THE MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN MOUSE COLON ADENOCARCINOMA CO38
    Cancer chemotherapy and pharmacology
    
    L. Massaad et al., "INFLUENCE OF TUMOR SIZE ON THE MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN MOUSE COLON ADENOCARCINOMA CO38", Cancer chemotherapy and pharmacology, 34(6), 1994, pp. 497-502
21. CHABOT GG
    FACTORS INVOLVED IN CLINICAL-PHARMACOLOGY VARIABILITY IN ONCOLOGY
    Anticancer research
    
    G.G. Chabot, "FACTORS INVOLVED IN CLINICAL-PHARMACOLOGY VARIABILITY IN ONCOLOGY", Anticancer research, 14(6A), 1994, pp. 2269-2272
22. RIBRAG V; MASSAAD L; JANOT F; BISSERY MC; PARISE O; GOUYETTE A; CHABOT GG
    PRINCIPAL DRUG-METABOLIZING ENZYME-SYSTEMS IN L1210 LEUKEMIA SENSITIVE OR RESISTANT TO BCNU IN-VIVO
    Leukemia research
    
    V. Ribrag et al., "PRINCIPAL DRUG-METABOLIZING ENZYME-SYSTEMS IN L1210 LEUKEMIA SENSITIVE OR RESISTANT TO BCNU IN-VIVO", Leukemia research, 18(11), 1994, pp. 829-835
23. DEFORNI M; BUGAT R; CHABOT GG; CULINE S; EXTRA JM; GOUYETTE A; MADELAINE I; MARTY ME; MATHIEUBOUE A
    PHASE-I AND PHARMACOKINETIC STUDY OF THE CAMPTOTHECIN DERIVATIVE IRINOTECAN, ADMINISTERED ON A WEEKLY SCHEDULE IN CANCER-PATIENTS
    Cancer research
    
    M. Deforni et al., "PHASE-I AND PHARMACOKINETIC STUDY OF THE CAMPTOTHECIN DERIVATIVE IRINOTECAN, ADMINISTERED ON A WEEKLY SCHEDULE IN CANCER-PATIENTS", Cancer research, 54(16), 1994, pp. 4347-4354
24. ABIGERGES D; ARMAND JP; CHABOT GG; DACOSTA L; FADEL E; COTE C; HERAIT P; GANDIA D
    IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA
    Journal of the National Cancer Institute
    
    D. Abigerges et al., "IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA", Journal of the National Cancer Institute, 86(6), 1994, pp. 446-449
25. DEFORNI M; CHABOT GG; ARMAND JP; FONTANA X; RECONDO G; DOMENGE C; CARDE P; BARBU M; GOUYETTE A
    PHASE-I AND PHARMACOKINETIC STUDY OF BREQUINAR (DUP-785 NSC-368390) IN CANCER-PATIENTS
    European journal of cancer
    
    M. Deforni et al., "PHASE-I AND PHARMACOKINETIC STUDY OF BREQUINAR (DUP-785 NSC-368390) IN CANCER-PATIENTS", European journal of cancer, 29A(7), 1993, pp. 983-988
26. RIBRAG V; DROZ JP; MORIZET J; LECLERCQ B; GOUYETTE A; CHABOT GG
    TEST DOSE-GUIDED ADMINISTRATION OF CISPLATIN IN AN ANEPHRIC PATIENT -A CASE-REPORT
    Annals of oncology
    
    V. Ribrag et al., "TEST DOSE-GUIDED ADMINISTRATION OF CISPLATIN IN AN ANEPHRIC PATIENT -A CASE-REPORT", Annals of oncology, 4(8), 1993, pp. 679-682
27. JANOT F; MASSAAD L; RIBRAG V; DEWAZIERS I; BEAUNE PH; LUBOINSKI B; PARISE O; GOUYETTE A; CHABOT GG
    PRINCIPAL XENOBIOTIC-METABOLIZING ENZYME-SYSTEMS IN HUMAN HEAD AND NECK SQUAMOUS-CELL CARCINOMA
    Carcinogenesis
    
    F. Janot et al., "PRINCIPAL XENOBIOTIC-METABOLIZING ENZYME-SYSTEMS IN HUMAN HEAD AND NECK SQUAMOUS-CELL CARCINOMA", Carcinogenesis, 14(7), 1993, pp. 1279-1283
28. TOUSSAINT C; ALBIN N; MASSAAD L; GRUNENWALD D; PARISE O; MORIZET J; GOUYETTE A; CHABOT GG
    MAIN DRUG-METABOLIZING AND CARCINOGEN-METABOLIZING ENZYME-SYSTEMS IN HUMAN NONSMALL CELL LUNG-CANCER AND PERITUMORAL TISSUES
    Cancer research
    
    C. Toussaint et al., "MAIN DRUG-METABOLIZING AND CARCINOGEN-METABOLIZING ENZYME-SYSTEMS IN HUMAN NONSMALL CELL LUNG-CANCER AND PERITUMORAL TISSUES", Cancer research, 53(19), 1993, pp. 4608-4612
29. ALBIN N; MASSAAD L; TOUSSAINT C; MATHIEU MC; MORIZET J; PARISE O; GOUYETTE A; CHABOT GG
    MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN HUMAN BREAST-TUMORS AND PERITUMORAL TISSUES
    Cancer research
    
    N. Albin et al., "MAIN DRUG-METABOLIZING ENZYME-SYSTEMS IN HUMAN BREAST-TUMORS AND PERITUMORAL TISSUES", Cancer research, 53(15), 1993, pp. 3541-3546
30. MASSAAD L; DEWAZIERS I; RIBRAG V; JANOT F; MORIZET J; BEAUNE PH; GOUYETTE A; CHABOT GG
    SCREENING OF MAIN DRUG-METABOLIZING-ENZYMES IN MOUSE AND HUMAN COLON TUMORS
    Bulletin du cancer
    
    L. Massaad et al., "SCREENING OF MAIN DRUG-METABOLIZING-ENZYMES IN MOUSE AND HUMAN COLON TUMORS", Bulletin du cancer, 80(5), 1993, pp. 397-407